肝脏超声造影诊断肝癌术后肝内肿瘤复发的价值探讨

doi:10.3969/j.issn.1672-5069.2016.02.024

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (2): 214-216.doi: 10.3969/j.issn.1672-5069.2016.02.024

肝脏超声造影诊断肝癌术后肝内肿瘤复发的价值探讨

王文娟, 白梅, 蔡江涛, 韩东刚

710054 西安市武警陕西省总队医院特诊科（王文娟,白梅,蔡江涛）; 西安交通大学第二附属医院超声研究室（韩东刚）

收稿日期:2015-08-23 出版日期:2016-03-10 发布日期:2016-03-04
通讯作者: 韩东刚,E-mail：handonggang41@163.com
作者简介:王文娟,女, 32岁,大学本科,医师。主要从事心血管超声诊断研究。E-mail：wangwenjuan565@163.com

Contrast-enhanced ultrasonography in the diagnosis of intrahepatic tumor recurrence in patients with hepatocellular carcinoma after hepatectomy

Wang Wenjuan, Bai Mei, Cai Jiangtao

Department of Ultrasonography, Shanxi General Hospital of CAPF, Xi'an 710054, Shaanxi Province, China

Received:2015-08-23 Online:2016-03-10 Published:2016-03-04

摘要/Abstract

摘要： 目的探讨超声造影在肝癌术后肝内肿瘤复发中的诊断价值。方法48例肝癌切除术后患者经常规超声检查发现肝内直径≤2.0 cm的单发病灶患者进行超声造影检查和血清AFP检测。结果在术后平均（32.86±7.54）个月,常规超声检查发现48例肝癌术后患者肝内出现直径≤2.0 cm单发病灶,48个单发病灶呈圆形或者类圆形占位性病变,其中44个呈低回声,4个呈高回声;超声造影检查判断肿瘤复发病灶35个,良性结节13个;在32例血清AFP>200 μg/L患者,肝内肿瘤发生率为87.50%,明显高于16例血清AFP≤200 μg/L患者的43.75%,具有统计学差异（x²=10.338,P=0.001）;在48个单发病灶中,超声造影诊断正确44个（91.67%）,包括复发病灶33个和良性结节11个;超声造影对肝癌术后患者肝内直径≤2.0 cm单发病灶诊断的准确度为91.67%（44/48）,灵敏度为94.29%（33/35）,特异度为84.62%（11/13）。结论超声造影可以对肝癌术后患者肝内复发病灶进行早期诊断,对于提高患者的治疗疗效和生存期具有重要的临床意义。

关键词: 肝细胞癌, 超声造影, 肿瘤复发, 诊断

Key words: Hepatocellular carcinoma, Contrast-enhanced ultrasonography, Recurrence, Diagnosis

王文娟, 白梅, 蔡江涛, 韩东刚. 肝脏超声造影诊断肝癌术后肝内肿瘤复发的价值探讨[J]. 实用肝脏病杂志, 2016, 19(2): 214-216.

Wang Wenjuan, Bai Mei, Cai Jiangtao. Contrast-enhanced ultrasonography in the diagnosis of intrahepatic tumor recurrence in patients with hepatocellular carcinoma after hepatectomy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 214-216.

参考文献

[1] Honjo M,Moriyasu F,Sugimoto K,et al. Relationship between the liver tissue shear modulus and histopathologic findings analyzed by intraoperative shear wave elastography and digital microscopically assisted morphometry in patients with hepatocellular carcinoma. J Ultrasound Med,2014,33（1）:61-71.
[2] Cha MJ,Lee MW,Cha DI,et al. Size discrepancy between sonographic and computed tomographic/magnetic resonance imaging measurement of hepatocellular carcinoma:the necessity of tumor size measurement standardization. J Ultrasound Med, 2013,32（10）:1703-1709.
[3] 周伟平,尹磊,吴孟超,等. 抗病毒治疗在HBV相关肝癌综合治疗中的作用. 实用肝脏病杂志,2015,18（2）:115-117.
[4] Huang S,Yu J,Liang P,et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels:A long-term follow-up. Eur J Radiol,2014,83（3）:552-558.
[5] 王松贤. 慢性乙型肝炎患者肝组织学检查的意义.实用肝脏病杂志,2014,17（3）:297-298.
[6] Numata K, Fukuda H,Miwa H,et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol, 2014,83（1）:95-102.
[7] Numata K,Fukuda H,Miwa H,et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol, 2014,83（1）:95-102.
[8] Zhu J,Zhu H,Mei Z,et al. High-intensity focused ultrasound ablation for treatment of hepatocellular carcinoma andhypersplenism:preliminary study. J Ultrasound Med,2013,32（10）:1855-1862.
[9] Choi JI, Jung SE,Kim PN,et al. Quality assurance in ultrasound screening for hepatocellular carcinoma using a standardized phantom and standard clinical images:A 3-year national investigation in Korea. J Ultrasound Med,2014,33（6）:985-995.
[10] Takizawa K,Numata K,Morimoto M,et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol,2013,82（9）:1471-1480.
[11] Niu Y,Huang T,Lian F,et al. Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma:A meta-analysis and meta-regression analysis. Tumour Biol,2013, 34（6）:3667-3674.
[12] Wang L,Yao M,Dong Z,et al. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol,2014,35（1）:9-20.
[13] Frampas E,Lassau N,Zappa M,et al. Advanced hepatocellular carcinoma:Early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Eur J Radiol,2013,82（5）:e205-e211.
[14] 崔贤,李开艳,张喜君,等.超声造影在肝癌术后患者中早期诊断复发的应用. 中国超声医学杂志,2011,27（6）:539-542.
[15] Sato K,Tanaka S,Mitsunori Y,et al. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma:Clinical and biological significance. Hepatology, 2013,57（4）:1436-1447.
[16] Kita R,Sakamoto A,Nagata Y,et al. Visualization of blood drainage area from hypervascular hepatocellular carcinoma on ultrasonographic images during hepatic arteriogram:Comparison with depiction of drainage area on contrast-enhanced ultrasound. Hepatol Res,2012,42（10）:999-1007.
[17] Kazue S,Manabu W. Usefulness of contrast-enhanced ultrasonography in the diagnosis of ruptured hepatocellular carcinoma. Clin J Gastroenterol,2013,6（4）:334-337.
[18] Arii S,Tanaka S,Mitsunori Y,et al. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. Oncology,2010,78（Suppl 1）:125-130.

肝脏超声造影诊断肝癌术后肝内肿瘤复发的价值探讨

Contrast-enhanced ultrasonography in the diagnosis of intrahepatic tumor recurrence in patients with hepatocellular carcinoma after hepatectomy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[5]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[6]	叶显俊, 何年安, 隋秀芳, 刘力. 二维超声和超声造影检查肝脏上皮样血管内皮瘤表现特征分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 904-907.
[7]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[8]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[11]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[12]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[13]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[14]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[15]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.